All causes of death · people requiring prevention of venous thromboembolism
Fondaparinux showed no clear difference in all causes of death compared with LMWH (moderate certainty).
1 finding from 1 review
Total VTE · people requiring prevention of venous thromboembolism
1 finding from 1 review
Symptomatic VTE · people requiring prevention of venous thromboembolism
1 finding from 1 review
Deep vein thrombosis · people requiring prevention of venous thromboembolism
1 finding from 1 review
Proximal DVT · people requiring prevention of venous thromboembolism
1 finding from 1 review
Total PE · people requiring prevention of venous thromboembolism
1 finding from 1 review
Symptomatic VTE · people requiring prevention of venous thromboembolism
Fondaparinux leads to lower symptomatic VTE compared with placebo (high certainty).
1 finding from 1 review
Major bleeding · people requiring prevention of venous thromboembolism
It is very uncertain whether fondaparinux changes major bleeding compared with variable dose warfarin (very low certainty).
1 finding from 1 review
All causes of death · people requiring prevention of venous thromboembolism
1 finding from 1 review
Total VTE · people requiring prevention of venous thromboembolism
It is very uncertain whether fondaparinux changes total VTE compared with 1 mg warfarin (very low certainty).
1 finding from 1 review
Symptomatic VTE · people requiring prevention of venous thromboembolism
1 finding from 1 review
Deep vein thrombosis · people requiring prevention of venous thromboembolism
It is very uncertain whether fondaparinux changes total DVT compared with 1 mg warfarin (very low certainty).
1 finding from 1 review
Proximal DVT · people requiring prevention of venous thromboembolism
1 finding from 1 review
Total PE · people requiring prevention of venous thromboembolism
1 finding from 1 review
Major bleeding · people requiring prevention of venous thromboembolism
It is very uncertain whether fondaparinux changes major bleeding compared with 1 mg warfarin (very low certainty).
1 finding from 1 review
All causes of death · people requiring prevention of venous thromboembolism
1 finding from 1 review
Total VTE · people requiring prevention of venous thromboembolism
1 finding from 1 review
Deep vein thrombosis · people requiring prevention of venous thromboembolism
Fondaparinux probably leads to lower total DVT compared with placebo (moderate certainty).
1 finding from 1 review
Symptomatic VTE · people requiring prevention of venous thromboembolism
1 finding from 1 review
Deep vein thrombosis · people requiring prevention of venous thromboembolism
1 finding from 1 review